Direkt zum Inhalt
Merck

Protein Drug Targets of Lavandula angustifolia on treatment of Rat Alzheimer's Disease.

Iranian journal of pharmaceutical research : IJPR (2015-01-07)
Hakimeh Zali, Mona Zamanian-Azodi, Mostafa Rezaei Tavirani, Alireza Akbar-Zadeh Baghban
ZUSAMMENFASSUNG

Different treatment strategies of Alzheimer's disease (AD) are being studied for treating or slowing the progression of AD. Many pharmaceutically important regulation systems operate through proteins as drug targets. Here, we investigate the drug target proteins in beta-amyloid (Aβ) injected rat hippocampus treated with Lavandula angustifolia (LA) by proteomics techniques. The reported study showed that lavender extract (LE) improves the spatial performance in AD animal model by diminishing Aβ production in histopathology of hippocampus, so in this study neuroprotective proteins expressed in Aβ injected rats treated with LE were scrutinized. Rats were divided into three groups including normal, Aβ injected, and Aβ injected that was treated with LE. Protein expression profiles of hippocampus tissue were determined by two-dimensional electrophoresis (2DE) method and dysregulated proteins such as Snca, NF-L, Hspa5, Prdx2, Apoa1, and Atp5a1were identified by MALDI-TOF/TOF. KEGG pathway and gene ontology (GO) categories were used by searching DAVID Bioinformatics Resources. All detected protein spots were used to determine predictedinteractions with other proteins in STRING online database. Different isoforms of important protein, Snca that exhibited neuroprotective effects by anti-apoptotic properties were expressed. NF-L involved in the maintenance of neuronal caliber. Hspa5 likewise Prdx2 displays as anti-apoptotic protein that Prdx2 also involved in the neurotrophic effects. Apoa1 has anti-inflammatory activity and Atp5a1, produces ATP from ADP. To sum up, these proteins as potential drug targets were expressed in hippocampus in response to effective components in LA may have therapeutic properties for the treatment of AD and other neurodegenerative diseases.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Jodacetamid, BioUltra
Sigma-Aldrich
DL-Dithiothreitol -Lösung, BioUltra, Molecular Biology, ~1 M in H2O
Sigma-Aldrich
Jodacetamid, Single use vial of 56 mg
Sigma-Aldrich
Harnstoff, powder, BioReagent, Molecular Biology, suitable for cell culture
Sigma-Aldrich
Jodacetamid, ≥99% (NMR), crystalline
Supelco
DL-Dithiothreitol -Lösung, 1 M in H2O
Sigma-Aldrich
Harnstoff, ACS reagent, 99.0-100.5%
Supelco
Harnstoff, 8 M (after reconstitution with 16 mL high purity water)
Sigma-Aldrich
Harnstoff -Lösung, BioUltra, ~8 M in H2O
Sigma-Aldrich
Harnstoff, ReagentPlus®, ≥99.5%, pellets
Sigma-Aldrich
Harnstoff, BioUltra, Molecular Biology, 99% (T)
Sigma-Aldrich
Harnstoff, BioXtra, pH 7.5-9.5 (20 °C, 5 M in H2O)
Sigma-Aldrich
Harnstoff, suitable for electrophoresis
Sigma-Aldrich
Harnstoff, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%, 99.0-101.0% (calc. on dry substance)
Sigma-Aldrich
MES -Lösung, BioUltra, Molecular Biology, 0.5 M in H2O
Supelco
Harnstoff, analytical standard
Sigma-Aldrich
Harnstoff, meets USP testing specifications
SAFC
Jodacetamid
USP
Harnstoff, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
3-[(3-Cholamidopropyl)dimethylammonio]-1-propansulfonat Hydrat, 98%
Sigma-Aldrich
Harnstoff, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99%
Sigma-Aldrich
Harnstoff -Lösung, 40 % (w/v) in H2O
Millipore
Harnstoff -Lösung, suitable for microbiology, 40% in H2O
Harnstoff, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Harnstoff-12C, 99.9 atom % 12C
Sigma-Aldrich
ATPA, solid